More cuts to come by March!

Quote

Anonymous

Guest
Close contact at Home office informed me that they are mapping territories and preparing for a very large cut. I've seen the writing on the wall for awhile but this confirms everything. I wish Everyone the best! Keeps our finger crossed
 
























Anonymous said:
what incompetent fool covers for MM?
That whole department is like 0 wins for 1000 attempts...not including BCBS of Idaho.
Click to expand...

I have to agree with this post! All the SAM's are held accountable for sales in their territory and viability but we have a Managed Care team that literally has not one win for Zohydro. The only changes in formulary status are more restrictions or in the case of Express Scripts, no coverage. Then at every chance they have some quote about great coverage. We need a MM team who supports the sales team, not hinders or does nothing.
 






If you talentless, lazy reps could sell then you would create pull through. Us in MM do are job at a high level. Do your job. Of course you can't and that is why you are still field reps. See ya losers!
 






FORM 8-K (Filed Today!!) Explained to the Novices on this board
Some of you will be too lazy or moronic to look this up so here's the KEY portion of the information released.

"On January 12, 2015, Zogenix, Inc. (the "Company" or "Zogenix") announced that its preliminary unaudited cash and cash equivalents as of December 31, 2014 were approximately $42.2 million, including $21.5 million in cash from a term loan and a revolving line of credit with Oxford Finance LLC and Silicon Valley Bank. In addition, $8.5 million is being held in escrow from the proceeds of the sale of Sumavel DosePro to Endo Pharmaceuticals."

Essentially they admitted that they are running low on cash again... half of their cash is from a term loan and they will be cautious about using that money... in a nutshell, they have 20.7 million to play with and that is DANGEROUSLY LOW for a High Spend / Low Sales tiny little biotech.... they will DILUTE witihin the NEXT FEW MONTHS... The MATH IS EASY to understand here... Low cash, High Cash Burn Rate = BIG TROUBLE!

The loan cash is only to mask how little REAL MONEY they have on hand... they will not use the loan cash for anything but to make it appear they have a stronger balance sheet.... Zohydro Sales are DISMAL and about to get worse with release of Hysingla ER by Purdue Pharma later this month.

BE VERY CAUTIOUS HERE!!!
 






Anonymous said:
FORM 8-K (Filed Today!!) Explained to the Novices on this board
Some of you will be too lazy or moronic to look this up so here's the KEY portion of the information released.

"On January 12, 2015, Zogenix, Inc. (the "Company" or "Zogenix") announced that its preliminary unaudited cash and cash equivalents as of December 31, 2014 were approximately $42.2 million, including $21.5 million in cash from a term loan and a revolving line of credit with Oxford Finance LLC and Silicon Valley Bank. In addition, $8.5 million is being held in escrow from the proceeds of the sale of Sumavel DosePro to Endo Pharmaceuticals."

Essentially they admitted that they are running low on cash again... half of their cash is from a term loan and they will be cautious about using that money... in a nutshell, they have 20.7 million to play with and that is DANGEROUSLY LOW for a High Spend / Low Sales tiny little biotech.... they will DILUTE witihin the NEXT FEW MONTHS... The MATH IS EASY to understand here... Low cash, High Cash Burn Rate = BIG TROUBLE!

The loan cash is only to mask how little REAL MONEY they have on hand... they will not use the loan cash for anything but to make it appear they have a stronger balance sheet.... Zohydro Sales are DISMAL and about to get worse with release of Hysingla ER by Purdue Pharma later this month.

BE VERY CAUTIOUS HERE!!!
Click to expand...

Just read the 8k!! Looks like we'll all be looking for a job within the next few months. Doesn't look like they will the money for severance either.
 






Anonymous said:
If you talentless, lazy reps could sell then you would create pull through. Us in MM do are job at a high level. Do your job. Of course you can't and that is why you are still field reps. See ya losers!
Click to expand...

Us in MM do ARE job at a high level? Like how? Emailing a third party purchased vendor report?
You shitheads think because you get PBM access it's game over? Listen r***** - that is step one. Step two is leaving your house and knocking on the doors of a regional plan for formulary inclusion. Plans do not automatically add drug because the PBM says sure. Without the plan allowing access you come pull through a $250+ drug in a generic space.

BTW- keep telling Roger we are covered. Idiots.
 






Anonymous said:
Us in MM do ARE job at a high level? Like how? Emailing a third party purchased vendor report?
You shitheads think because you get PBM access it's game over? Listen r***** - that is step one. Step two is leaving your house and knocking on the doors of a regional plan for formulary inclusion. Plans do not automatically add drug because the PBM says sure. Without the plan allowing access you come pull through a $250+ drug in a generic space.

BTW- keep telling Roger we are covered. Idiots.
Click to expand...

You are calling them idiots but you are the one that doesnt seem to understand that this person is a troll and not in managed markets. Get a clue.
 












Anonymous said:
Us in MM do ARE job at a high level? Like how? Emailing a third party purchased vendor report?
You shitheads think because you get PBM access it's game over? Listen r***** - that is step one. Step two is leaving your house and knocking on the doors of a regional plan for formulary inclusion. Plans do not automatically add drug because the PBM says sure. Without the plan allowing access you come pull through a $250+ drug in a generic space.

BTW- keep telling Roger we are covered. Idiots.
Click to expand...


So typical for mm to use the word "are" jobs when proper english would state "our" job. No wonder we are in the shape we are in. RH or maybe BM trained you on how to speak to your peers.
 












doesn't matter. Day 1 H is T3 everywhere.
Year 2 ZER is on nothing except Tricare.
60 days H will eat up all Z RX's - covered plus copay cards?

I mean really. A conference call that discussed ADT, Efficacy and Rescue Doses? You dumb fucks - yea all of you in SD - leave the building. You have been inside too long. This market is 100% payer driven and my MM is a dumbass.

Recognize the real problem is the 4th issue Kelly tried to sweep under the rug. Listen sweetie - at the end of the call T3 will move business. Not ZER Express.
 






Anonymous said:
doesn't matter. Day 1 H is T3 everywhere.
Year 2 ZER is on nothing except Tricare.
60 days H will eat up all Z RX's - covered plus copay cards?

I mean really. A conference call that discussed ADT, Efficacy and Rescue Doses? You dumb fucks - yea all of you in SD - leave the building. You have been inside too long. This market is 100% payer driven and my MM is a dumbass.

Recognize the real problem is the 4th issue Kelly tried to sweep under the rug. Listen sweetie - at the end of the call T3 will move business. Not ZER Express.
Click to expand...

This prediction might be right, but it doesn't have to be. Payers don't care about ADT. They care about cost. Z could have gained big market share if it realized the writing on the wall; deep discounts are the only path to get them to their ADT launch.
 












Top Bottom
Back
Quote